Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model

Article Oncology

Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin

Robert A. Nagourney et al.

Summary: Patients with colon cancer who have received specific drug treatments are more likely to exhibit resistance to oxaliplatin, reducing the efficacy of heated intraperitoneal chemotherapy (HIPEC).

EJSO (2021)

添加到收藏夹

Article Oncology

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial

Francois Quenet et al.

Summary: This study aimed to evaluate the specific benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery compared with receiving cytoreductive surgery alone in patients with colorectal peritoneal metastases. The results showed no significant overall survival benefit after adding HIPEC, with more frequent postoperative late complications, suggesting that cytoreductive surgery alone should be prioritized as a treatment strategy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Genetics & Heredity

Consensuses and controversies on pseudomyxoma peritonei: a review of the published consensus statements and guidelines

Yu-Lin Lin et al.

Summary: PMP is a clinical malignant syndrome mainly originating from the appendix, making early and accurate diagnosis difficult. CRS + HIPEC has been established as an effective treatment for PMP and recommended globally. While there are some consensuses on PMP management, controversies exist worldwide, driving the continuous refinement and updating of consensuses.

ORPHANET JOURNAL OF RARE DISEASES (2021)

添加到收藏夹

Article Surgery

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery

Shigeki Kusamura et al.

Summary: This cohort study compared outcomes between PMP patients undergoing CRS with HIPEC and CRS alone, finding HIPEC to be associated with improved overall survival.

JAMA SURGERY (2021)

添加到收藏夹

Article Oncology

Limitations of the PRODIGE 7 trial

Koen P Rovers et al.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7

Peter Cashin et al.

Summary: Adjustments to the HIPEC protocol were suggested based on criticisms of the PRODIGE 7 trial, including improving the efficacy of HIPEC, the perioperative use of FOLFOX, or a return to HIPEC with mitomycin C.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Preclinical In Vivo-Models to Investigate HIPEC; Current Methodologies and Challenges

Roxan F. C. P. A. Helderman et al.

Summary: The efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) depends on various factors, including patient selection, tumor type, delivery technique, and treatment parameters. Preclinical research plays a crucial role in investigating and potentially improving treatment protocols. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature, providing recommendations and highlighting possible pitfalls in the experimental design.

CANCERS (2021)

添加到收藏夹

Article Oncology

Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging

Marion Larroque et al.

Summary: This study used mass spectrometry imaging techniques to analyze the penetration of oxaliplatin in ovaries during HIPEC treatment, revealing the distribution pattern of platinum and raising concerns about the potential toxicity in cases of combined treatments.

PLEURA AND PERITONEUM (2021)

添加到收藏夹

Article Oncology